Blast crisis of chronic granulocytic leukemia

Morphologic variants and therapeutic implications
      This paper is only available as a PDF. To read, Please Download here.


      Chronic granulocytic leukemia (CGL) terminates in a disease similar to acute leukemia. Except for a study indicating an increased response rate to the drugs, vincristine and prednisone, therapy of this terminal phase has been universally disappointing. We have studied the bone marrows and clinical courses of 67 patients in the terminal phase of CGL to discern if any parameters were associated with an increased response rate or survival. The results of this study indicate that patients who have a lymphoblastic morphology or hypodiploid cytogenetics in the terminal phase respond better to treatment with the combination of vincristine and prednisone than those with myeloblastic morphology or hyperdiploid cytogenetics. Response rate and survival are significantly increased in those with lymphoblastic morphology. Recognition of the heterogeneity of the terminal phase of CGL may dictate specific therapeutic modalities.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Canellos GP
        • DeVita VT
        • Whang-Peng J
        • et al.
        Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia.
        Blood. 1971; 38: 671
        • Peterson LC
        • Bloomfield CD
        • Brunning RD
        Blast crisis as an initial or terminal manifestation of chronic myeloid leukemia.
        Am J Med. 1976; 60: 209
        • Sarin PS
        • Anderson PN
        • Gallo RC
        Terminal deoxynucleotidyl transferase activities in human blood leukocytes and lymphoblast cell lines: high levels in lymphoblast cell lines and in blast cells of some patients with chronic myelogenous leukemia in acute phase.
        Blood. 1976; 47: 11
        • Gralnick HR
        • Harbor J
        • Vogel C
        Myelofibrosis in chronic granulocytic leukemia.
        Blood. 1971; 37: 152
        • Rutenberg AS
        • Rosales J
        • Bennett JM
        An improved histochemical method for the determination of leukocyte alkaline phosphatase.
        J Lab Clin Med. 1965; 65: 698
        • Tjio JH
        • Whang J
        Chromosome preparations in bone marrow cells without prior in vitro culture or in vivo colchicine administration.
        Stain Technol. 1962; 37: 17
        • Canellos GP
        • Young RC
        • Nieman PE
        • et al.
        Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan.
        Blood. 1975; 45: 197
        • Ihde DC
        • Canellos GP
        • Schwartz JH
        • et al.
        Splenectomy in the chronic phase of chronic granulocytic leukemia.
        Ann Intern Med. 1976; 84: 17
        • Schwartz JH
        • Canellos GP
        Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia.
        Blood. 1975; 46: 11
        • Canellos GP
        • DeVita VT
        • Whang-Peng J
        • et al.
        Chemotherapy of the blastic phase of chronic granulocytic leukemia: effect of hypodiploidy.
        Blood. 1976; 47: 1003
        • Rundles RW
        Chronic granulocytic leukemia.
        in: Williams WJ Beutler E Erslev AJ Rundles RW Hematology. McGraw-Hill Book Co, New York1972: 690
        • Gralnick HR
        • Bennett JM
        Bone-marrow histology in chronic granulocytic leukemia: observations on myelofibrosis and the accelerated phase.
        in: Clarke WJ Howard EB Hackett PL Myeloproliferative Disorders of Animals and Man. U.S. Atomic Energy Commission, June 1970: 583
        • Marmont AM
        • Damasio EE
        The treatment of terminal metamorphosis of chronic granulocytic leukemia with corticosteroids and vincristine.
        Acta Haematol. 1973; 50: 1
        • Forman EN
        • Barker BE
        • Farnes P
        Evidence for lymphoid and myeloid properties of blast cells in chronic myelocytic leukemia of children (abstract).
        in: Program of the American Society of Hematology. 1975: 59 (Dallas, Texas)
        • Shaw MT
        • Bottomley RH
        • Grozea PN
        • et al.
        Heterogeneity of morphological, cytochemical, and cytogenetic features in the blastic phase of chronic granulocytic leukemia.
        Cancer. 1975; 35: 199
        • Ben-Zeev D
        • Schwartz SO
        • Friedman IA
        Promyelocytic-myelocytic leukemia as a terminal manifestation of chronic granulocytic leukemia.
        Blood. 1966; 27: 863
        • McCaffrey R
        • Greaves M
        • Harrison TA
        • et al.
        Biochemical and immunological evidence for a lymphoblastic conversion in chronic myelogenous leukemia (abstract).
        in: Program of the American Society of Hematology. 1975: 89 (Dallas, Texas)
        • Pollack MS
        • Slimp GH
        • Sokal JE
        Leukemia-associated antigen (LAA) in chronic leukemia: correlations with disease status (abstract).
        in: Program of the American Society of Hematology. 1975: 141 (Dallas, Texas)
        • Boggs DR
        Hematopoietic stem cell theory in relation to possible lymphoblastic conversion of chronic myeloid leukemia.
        Blood. 1974; 44: 449